Search Medical Condition
Please enter condition
Please choose location from dropdown

Carmagnola, Italy Clinical Trials

A listing of Carmagnola, Italy clinical trials actively recruiting patients volunteers.

RESULTS

Found (55) clinical trials

Evaluation of Safety and Efficacy of New Infant Formula in Infantile Colic

The study is conducted to examine the safety and efficacy of a new infant formula and its effects on the gastrointestinal tolerance in infants suffering from colic. Primary hypothesis to be tested is: an infant formula with optimized composition improves colicky symptoms compared to a standard formula.

Phase N/A

2.36 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma

The purpose of this study is to evaluate the overall response rate (ORR) of pemigatinib as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring FGF/FGFR alterations.

Phase

8.87 miles

Learn More »

FIL Study on ABVD DD-DI as Upfront Therapy in HL.

The study is devoted to patients affected with advanced stage (IIB-IV) Hodgkin Lymphoma. The study aims to compare the efficacy of two alternative ABVD-based strategies, the first one (Comparator arm) based on a PET-2-adaptation, the second (Experimental arm) relying on a straight dose- and time-intensified schedule, devoid of any PET-adaptation. ...

Phase

9.7 miles

Learn More »

Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant

Allogeneic hematopoietic cell transplantation (HCT) remains the only curative approach for many hematological malignancies. In allogeneic HCT the donor immune system through the donor lymphocytes exerts both a beneficial and detrimental effect. Graft versus host disease (GVHD) represents the major complication and cause of mortality of allogeneic HCT. The principal ...

Phase N/A

9.7 miles

Learn More »

Overcoming Endocrine Resistance in Metastatic Breast Cancer

In presence of ER hypersensitivity even a small amount of ER may be sufficient for sustained growth signalling. On the other hand, ER disruption operated by fulvestrant is not complete, particularly in the initial phase of treatment. From phase III trials, indeed, The invertigators know that with the standard 250mg ...

Phase

9.7 miles

Learn More »

Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma

This is a multicenter, randomized, phase III, superiority study comparing standard vs response driven approach to maintenance. Adult patients (age 18 years) with nave, untreated follicular lymphoma, stage II-IV, Follicular Lymphoma International Prognostic Index 2 (FLIPI2) >0 requiring a therapeutic intervention will be recruited and randomly assigned in a 1:1 ...

Phase

9.7 miles

Learn More »

ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma

The Primary objective is: Overall survival in patient with non metastatic osteosarcoma of the extremities treated with different chemotherapy approach (5 drugs vs 3 drugs), according to the expression of ABCB1/P-glycoprotein The Secondary objectives are: to assess the survival in patient who over express ABCB1/P-glycoprotein, with chemotherapy protocol based on ...

Phase

9.7 miles

Learn More »

Prospective Observational Study of Antitumor Activity Correlation Between Hormonal Therapy and Expression miRNA100

The potential role of miRNAs will be studied as a predictor of hormone sensitivity in hormone-positive breast carcinomas. The miRNA100 obtained on biopsy will be compared with the expression levels of those obtained from the surgically removed tumor, in order to assess the possible modulation of miRNA100 following hormonal treatment.

Phase N/A

9.7 miles

Learn More »

Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

Among Non-Hodgkin lymphomas (NHL), Follicular Lymphoma (FL) is the second one in terms of frequency, accounting for about 25% of all NHL cases in the western hemisphere. A predominance in females is reported, and the median age at the diagnosis is 60 years. FL cells originates from normal counterparts germinal ...

Phase

9.7 miles

Learn More »

A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP)

Treatment-nave patients with CUP diagnosis confirmed according to CUP Diagnostic Guidelines, will be enrolled into AGNOSTOS trial. Patients will be randomized upfront to receive a nab-paclitaxel-based duplet adding either carboplatin or gemcitabine until progression or unacceptable toxicity (randomization 1:1, n= 120; 60 per arm).

Phase

9.7 miles

Learn More »